Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
RET fusion
i
Other names:
RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5979
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
FoundationOne® CDx (110)
Oncomine™ Dx Target Test (10)
FoundationOne® CDx (110)
Oncomine™ Dx Target Test (10)
Associations
(62)
News
Trials
Search handles
@Al3ssandroRusso
@AndresFCardonaZ
@ArndtVogel
@BPothuri
@BenWestphalen
@BiagioMd
@CharuAggarwalMD
@ChristianRolfo
@DrJedDowell
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@GRecondoMD
@GautschiOliver
@JackWestMD
@Jbauml
@Latinamd
@LeciaSequist
@LuisERaez1
@MPishvaian
@NormandBlais
@PTarantinoMD
@RenoHemonc
@RielyMD
@StephenVLiu
@TiansterZhang
@UmutDisel
@VivekSubbiah
@antonyruggeri
@carlomcicala
@chulkimMD
@doctorC369
@dplanchard
@dr_yakupergun
@drallysonocean
@drenriquegrande
@herbloong
@mtmdphd
@neerajaiims
@pashtoonkasi
@schoffski
@sujithonco
@trnsltnl
@weldeiry
Search handles
@Al3ssandroRusso
@AndresFCardonaZ
@ArndtVogel
@BPothuri
@BenWestphalen
@BiagioMd
@CharuAggarwalMD
@ChristianRolfo
@DrJedDowell
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@GRecondoMD
@GautschiOliver
@JackWestMD
@Jbauml
@Latinamd
@LeciaSequist
@LuisERaez1
@MPishvaian
@NormandBlais
@PTarantinoMD
@RenoHemonc
@RielyMD
@StephenVLiu
@TiansterZhang
@UmutDisel
@VivekSubbiah
@antonyruggeri
@carlomcicala
@chulkimMD
@doctorC369
@dplanchard
@dr_yakupergun
@drallysonocean
@drenriquegrande
@herbloong
@mtmdphd
@neerajaiims
@pashtoonkasi
@schoffski
@sujithonco
@trnsltnl
@weldeiry
Filter by
Latest
9ms
Dr. @DDoroshow discusses RET fusions in NSCLC at #ILCC23 @gotoPER @MountSinaiNYC (@NarjustFlorezMD)
9 months ago
RET (Ret Proto-Oncogene)
|
RET fusion
9ms
Anti-cancer therapy targeting RET fusions 🧬💊 has received tissue-agnostic regulatory approval in solid tumors. In this Letter to the Editor, @mgoudaMD @viveksubbiah and coll. report on weight gain associated with brain penetrant RET-selective Inhibitors https://t.co/JPiQWElN6s (@Annals_Oncology)
9 months ago
Pan tumor
|
RET (Ret Proto-Oncogene)
|
RET fusion
10ms
Dr. @StephenVLiu presenting #RET, rare fusions in NSCLC and RNA-Sequencing. #TargetedTherapiesInLungCancer #LungCancer #CancerEducation #cancerGRACE (@cancerGRACE)
10 months ago
RET fusion
12ms
A great collaboration aimed at preventing RET fusion + CNS mets in NSCLC. https://t.co/IcFUezC2bW @alexdrilon @AlexiaIasonos (@YoninaMG)
12 months ago
RET (Ret Proto-Oncogene)
|
RET fusion
12ms
Nearly 1/2 of patients w/RET fusion+ stage IV #NSCLC develop brain metastases. Not only is #selpercatinib associated w/decreased rates of progression of #CNS disease, but early initiation may prevent development of #CNS metastases. https://t.co/B1ZKmL73SG @alexdrilon @YoninaMG (@JTOonline)
12 months ago
Clinical • Metastases
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
Retevmo (selpercatinib)
12ms
Do we even need clinical trials with Real World Data like this? Re-Evaluating Real-World Evidence in RET Fusion-Positive NSCLC: Are Randomized Clinical Trials Needed? @JTOonline -Editorial by @LovaSunMD @CharuAggarwalMD @MMarmarelis #lcsm https://t.co/pQsOfIqDBQ (@Latinamd)
12 months ago
Clinical • HEOR • Real-world evidence • Real-world
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
12ms
Central Nervous System Disease in Patients With #RET Fusion-Positive NSCLC Treated With Selpercatinib - @alexdrilon @JTOonline - In 31 pts with no baseline CNS Mets , incidence rate of new 🧠 Mets 0% at 3 yrs ( historically 40%) #lcsm https://t.co/Nj2leVbg9l (@Latinamd)
12 months ago
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Retevmo (selpercatinib)
12ms
An inspiring ending to the inaugural @MDAndersonNews Shelby Lavine #PancreaticCancer Research symposium by @VivekSubbiah on finding the “needle in a haystack” in this disease (with some remarkable examples of targeting RET fusion in PDAC). Fitting finale courtesy of ChatGPT! https://t.co/0BXOMj1yka (@Aiims1742)
12 months ago
RET (Ret Proto-Oncogene)
|
RET fusion
1year
What are emerging agents & combos to treat RET fusion-positive #NSCLC? Dr @alexdrilon from @MSKCancerCenter answers in 7 #CME minutes on YouTube: https://t.co/362Vf9bkdJ (@MedEdOTG)
1 year ago
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
1year
-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)
1 year ago
MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene)
|
RET fusion • MET exon 14 mutation • RET mutation
1year
-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)
1 year ago
MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene)
|
RET fusion • MET exon 14 mutation • RET mutation
1year
-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)
1 year ago
MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene)
|
RET fusion • MET exon 14 mutation • RET mutation
1year
Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers https://t.co/XkfJOctwuM (@AndresFCardonaZ)
1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor) • RET (Ret Proto-Oncogene)
|
EGFR mutation • RET fusion • RET mutation • RET positive
|
Tagrisso (osimertinib) • Retevmo (selpercatinib)
1year
More data to support paradigm of identifying additional drivers in NSCLC at time of resistance to first targeted therapy. In rare patients with EGFRm NSCLC that acquire RET fusions, osimertinib + selpercatinib leads to 50% resp rate. from @alexdrilon @MSK_DeptOfMed in @CCR_AACR (@RielyMD)
1 year ago
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
Tagrisso (osimertinib) • Retevmo (selpercatinib)
1year
Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial https://t.co/qavNgtbGcF (@VivekSubbiah)
1 year ago
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Retevmo (selpercatinib)
1year
Treatment-naïve RET fusion positive #NSCLC: how do we target therapy? Dr @alexdrilon from @MSKCancerCenter spends 7 minutes on our YouTube channel on strategies: https://t.co/3jJgXLQBWA (@MedEdOTG)
1 year ago
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
1year
For patients with EGFR-mutant NSCLC with an acquired RET fusion as a mechanism of EGFR inhibitor resistance, the addition of selpercatinib to osimertinib was feasible, safe, and offered clinical benefit, supporting the prospective evaluation of this combination. (@RETpositive)
1 year ago
Clinical
|
RET (Ret Proto-Oncogene)
|
EGFR mutation • RET fusion • RET mutation
|
Tagrisso (osimertinib) • Retevmo (selpercatinib)
1year
Happy to contribute, finally out: Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers https://t.co/PoPkMVi39V #LCSM @EGFRResisters (@trnsltnl)
1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor) • RET (Ret Proto-Oncogene)
|
EGFR mutation • RET fusion • RET mutation • RET positive
|
Tagrisso (osimertinib) • Retevmo (selpercatinib)
1year
-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)
1 year ago
MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene)
|
RET fusion • MET exon 14 mutation • RET mutation
1year
-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)
1 year ago
MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene)
|
RET fusion • MET exon 14 mutation • RET mutation
1year
Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer @JustinGainor #acscancerchat https://t.co/bTfdgSv5xA (@VivekSubbiah)
1 year ago
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
1year
First study showing RET as tissue agnostic target 👉Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial @NatureMedicine @JournalCancer #ACScancerchat @ADesaiMD @nehakred https://t.co/jGmz9d2rfl https://t.co/1cx6qOXjtG (@VivekSubbiah)
1 year ago
Clinical • Pan tumor
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
Gavreto (pralsetinib)
1year
Study leading to a tissue agnostic FDA approval in 2022 #RET 👉Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial @TheLancetOncol… https://t.co/zXwvIQlVOH (@VivekSubbiah)
1 year ago
Clinical • FDA event • Pan tumor
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Retevmo (selpercatinib)
1year
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial @TheLancetOncol #precisionmedicine #RET 🎯🧬 https://t.co/w5NUh8DVYN (@VivekSubbiah)
1 year ago
Clinical • Pan tumor
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Retevmo (selpercatinib)
1year
Drs. Pennell (@n8pennell) and Tafe (@LJTafeMD) highlight the importance of the #oncology #pathology partnership to fine-tune #biomarker testing and targeted tx of #lungcancer with #RET fusions to improve outcomes in this new #MedEd activity https://t.co/khqdclKlQh (@PeerView)
1 year ago
Licensing / partnership
|
RET (Ret Proto-Oncogene)
|
RET fusion
1year
Happy to share our case report 'Response to #selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma (LCNEC)' Great work by Dr. Aakriti Arora @MedStarWHC who is starting her fellowship in hem/onc this year! https://t.co/WoJSdktuVG (@chulkimMD)
1 year ago
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Retevmo (selpercatinib)
1year
RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape https://t.co/3Cfd5NNJHE (@AndresFCardonaZ)
1 year ago
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
1year
Drs. Pennell (@n8pennell) and Tafe (@LJTafeMD) provide practical guidance for #biomarker driven #NSCLC care, focusing on #RET fusions, the latest tx advances, and important #pathology advice in this new #MedEd activity for the broader #LungCancer care team https://t.co/khqdclKlQh (@PeerView)
1 year ago
RET (Ret Proto-Oncogene)
|
RET fusion
1year
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology @OncoAlert https://t.co/3YSK5ytxdR (@VivekSubbiah)
1 year ago
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion • RET positive
|
Retevmo (selpercatinib)
1year
Selpercatinib in RET Fusion–Positive Solid Tumors Other Than Lung or Thyroid Malignancies - @ASCOPost https://t.co/3Tz98inSfA (@VivekSubbiah)
1 year ago
RET (Ret Proto-Oncogene)
|
RET fusion
|
Retevmo (selpercatinib)
1year
⭐️RET fusions are tissue agnostic targets & are actionable in pancreatic cancer. Selpercatinib is FDA approved for RET + cancers @TheLancetOncol @Aiims1742 @PanCAN @ShaalanBeg @aparna1024 @EileenMOReilly @OncoAlert @GABOUALFA https://t.co/w5NUh8DVYN https://t.co/vrjuLTxscW (@VivekSubbiah)
1 year ago
FDA event • Pan tumor
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
Retevmo (selpercatinib)
1year
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial - The Lancet Oncology @TheLancetOncol https://t.co/w5NUh8DVYN (@VivekSubbiah)
1 year ago
Clinical • Pan tumor
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Retevmo (selpercatinib)
1year
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial @NaturePortfolio BLOG https://t.co/uXFvcsGIeO (@VivekSubbiah)
1 year ago
Clinical • Pan tumor
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
Gavreto (pralsetinib)
1year
Drs. Pennell (@n8pennell) and Tafe (@LJTafeMD) highlight the importance of the #Oncology #Pathology partnership to fine-tune #biomarker testing and targeted tx of #LungCancer with #RET fusions to improve outcomes in this new #MedEd activity https://t.co/khqdclKlQh #MedTwitter (@PeerView)
1 year ago
Licensing / partnership
|
RET (Ret Proto-Oncogene)
|
RET fusion
1year
#OpenAccess in @trendscancer by @VivekSubbiah & Deepak Bhamidipati: Impact of tissue agnostic drugs in the tx of #patients w gastrointestinal #Cancers (FDA) approvals for: ✅MSI ✅NTRK & RET fusion ✅TMB⬆️ ✅BRAFV600E @OncoAlert 🚨#PrecisionMedicine https://t.co/nF43SFpCd0 (@BenWestphalen)
1 year ago
Clinical • FDA event • Pan tumor
|
RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF V600E • BRAF V600 • RET fusion
1year
Discussing the #unicorns in targets for #lungcancer: NRG1,NTRK,and RET fusions @DDoroshow @gotoPER #winterlung chair @JulieBrahmer with @FSkoulidis #DrChristineBaik #miami challenge for medical oncologists to keep up with so much data, side effects (@donnashort)
1 year ago
Adverse events
|
RET (Ret Proto-Oncogene) • NRG1 (Neuregulin 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
RET fusion • NRG1 fusion
1year
Results from the #PrecisionOncology ARROW trial identify the potential of #pralsetinib as a tissue-agnostic therapy, with anti-tumor activity in patients with RET fusion–positive solid tumors. @VivekSubbiah @curijoey #WorldCancerDay #NMEDclinical https://t.co/cpL1OGu9sm (@NatureMedicine)
1 year ago
Clinical • Pan tumor
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
Gavreto (pralsetinib)
over1year
Nearly 1-2% of NSCLC's harbor #RET fusions. This retrospective multi-center study from 31 cancer centers @JTOonline evaluates clinico-biological features and treatment outcomes in patients with RET+ #NSCLC. @mihaela_aldea @BenjaminBesseMD https://t.co/lEr2k2pMn7 #LCSM (@StephenVLiu)
over 1 year ago
Retrospective data
|
RET (Ret Proto-Oncogene)
|
RET fusion
over1year
Nearly 1-2% of NSCLC's harbor #RET fusions. This retrospective multi-center study evaluates clinico-biological features and treatment outcomes in patients with any-stage RET+ #NSCLC from 31 cancer centers. https://t.co/QIFQKiwozl #LCSM @mihaela_aldea @BenjaminBesseMD (@JTOonline)
over 1 year ago
Retrospective data
|
RET (Ret Proto-Oncogene)
|
RET fusion
over1year
Drs. @YoninaMG @alexdrilon and team report on CNS disease in #RET fusion-positive NSCLC with selpercatinib @JTOonline. In pts with CNS metastases, only 20% with CNS progression at 3y. In pts without brain metastases, 0% (!) had CNS metastases at 3y. #LCSM https://t.co/DjgitIQoNF (@StephenVLiu)
over 1 year ago
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Retevmo (selpercatinib)
over1year
Central nervous system disease in patients with RET fusion-positive NSCLC treated with selpercatinib 61 pts ( 30 pts baseline CNS+) 💥Progression in those with CNS+ 6 and 36 mos➡️3% and 20% 💥CNS involvement in those with CNS- 36 mos➡️0% @JTOonline https://t.co/vtplvZA7RV (@dr_yakupergun)
over 1 year ago
Clinical
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET positive
|
Retevmo (selpercatinib)
over1year
RET-MAP study @JTOonline characterizes 218 pts with #RET fusion-positive NSCLC. 56% female, 93% adeno, 41% smokers, 72% with KIF5B. mTMB low (2.5 mt/Mb) and mPDL1 10%. CNS metastases in 21% at baseline, 31% overall. RR to chemo was 55% with mPFS 8.7m. https://t.co/IXBEW2NLY1 (@StephenVLiu)
over 1 year ago
Clinical
|
RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B)
|
RET fusion • TMB-L • RET positive
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login